Микрошунт PRESERFLO™ для микроинвазивной хирургии глаукомы

На сегодняшний день «золотым стандартом» хирургии глаукомы является трабекулэктомия, позволяющая достичь стойкого снижения внутриглазного давления (ВГД). Тем не менее, трабекулэктомия сравнительно травматична и ассоциируется с риском специфических осложнений. Вследствие этого к настоящему моменту был разработан ряд устройств для микроинвазивной хирургии глаукомы, предназначенных для создания сравнимого с трабекулэктомией гипотензивного эффекта вкупе с минимальной операционной травмой.

Микрошунт PRESERFLO™ (Santen) является полимерным микрошунтом для создания оттока внутриглазной жидкости под конъюнктиву с формированием фильтрационной подушки. Он имплантируется через субконъюнктивальный доступ, характерный для трабекулэктомии, однако, за счет контролируемого оттока влаги минимизирует риск развития осложнений, характерных для традиционных антиглаукомных вмешательств.

Долгосрочная (в сроки до 5 лет) эффективность и безопасность имплантации микрошунт PRESERFLO™ показаны в ряде исследований, в том числе сравнивающих PRESERFLO™ c другими операциями. Метаанализы, посвященные сравнению PRESERFLO™ и трабекулэктомии, показывают сравнимую эффективность вмешательств с меньшим риском осложнений у PRESERFLO™. Исследования, посвященные сравнению PRESERFLO™ и микрошунта похожей конструкции XEN (Allergan, Plc, Ирландия), показывают сравнимую либо лучшую эффективность PRESERFLO™.

1. GBD 2019 Blindness and Vision Impairment Collaborators. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health 2021; 9(2):e144-e160. https://doi.org/10.1016/S2214-109X(20)30489-7.

2. Tham Y.C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014; 121(11):2081-2090. https://doi.org/10.1016/j.ophtha.2014.05.013.

3. Нероев В.В., Михайлова Л.А., Малишевская Т.Н., Петров С.Ю., Филиппова О.М. Эпидемиология глаукомы в Российской Федерации. Российский офтальмологический журнал 2024; 17(3):7-12. https://doi.org/10.21516/2072-0076-2024-17-3-7-12.

4. Национальное руководство по глаукоме для практикующих врачей, 4-е издание, исправленное и дополненное. Под ред. Егорова Е.А., Еричева В.П. Москва: ГЭОТАР-Медиа 2019; 384.

5. European Glaucoma Society. Terminology and guidelines for glaucoma. Savona: PubliComm; 2020. 169 p.

6. Cairns J.E. Trabeculectomy. Preliminary report of a new method. Am J Ophthalmol 1968; 66(4):673-679.

7. Федоров С.Н., Козлов В.И., Тимошкина Н.Т., Шарова А.Б., Ерескин Н.Н., Козлова Е.Е. Непроникающая глубокая склерэктомия при открытоугольной глаукоме. Офтальмохирургия 1989; (3-4):52-55.

8. Agrawal P., Bradshaw S.E. Systematic Literature Review of Clinical and Economic Outcomes of Micro-Invasive Glaucoma Surgery (MIGS) in Primary Open-Angle Glaucoma. Ophthalmol Ther 2018; 7(1): 49-73. https://doi.org/10.1007/s40123-018-0131-0.

9. Silber S., Colombo A., Banning A.P., Hauptmann K., et al. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxeleluting stents for de novo coronary artery lesions. Circulation 2009; 120(15):1498-1504. https://doi.org/10.1161/CIRCULATIONAHA.109.849877.

10. Strickler F., Richard R., McFadden S., Lindquist J., et al. In vivo and in vitro characterization of poly(styrene-b-isobutylene-b-styrene) copolymer stent coatings for biostability, vascular compatibility and mechanical integrity. J Biomed Mater Res A 2010; 92(2):773-782. https://doi.org/10.1002/jbm.a.32418.

11. Kling J. The Lucrative Elution: Boston Scientific’s blockbuster medical device – and the novel way it was developed: MIT Technology Review; 2005. Available from: https://www.technologyreview.com/2005/10/01/101134/the-lucrative-elution/.

12. Pinchuk L., Riss I., Batlle J.F., Kato Y.P., et al. The development of a micro-shunt made from poly(styrene-block-isobutylene-blockstyrene) to treat glaucoma. J Biomed Mater Res B Appl Biomater 2017; 105(1):211-221. https://doi.org/10.1002/jbm.b.33525.

13. Acosta A.C., Espana E.M., Yamamoto H., Davis S., et al. A newly designed glaucoma drainage implant made of poly(styrene-b-isobutylene-b-styrene): biocompatibility and function in normal rabbit eyes. Arch Ophthalmol 2006; 124(12):1742-1749. https://doi.org/10.1001/archopht.124.12.1742.

14. Parel, J.M., Stoiber, J., Fernandez, V. Optical properties and biocompatibility of a novel polymer for intraocular implants: comparative study in the rabbit. (abstract). Ophthalmic Technologies XIV; 24–25 January 2004; San Jose 2004.

15. Arrieta E.A., Aly M., Parrish R., Dubovy S., et al. Clinicopathologic correlations of poly-(styrene-b-isobutylene-b-styrene) glaucoma drainage devices of different internal diameters in rabbits. Ophthalmic Surg Lasers Imaging 2011; 42(4):338-345. https://doi.org/10.3928/15428877-20110603-01.

16. Петров С.Ю., Волжанин А.В. Микрошунт XEN-45 для лечения глаукомы. Вестник офтальмологии 2018; 134(5):244-249. https://doi.org/10.17116/oftalma2018134051244.

17. Riss I., Batlle J., Pinchuk L., Kato Y.P., Weber B.A., Parel J.M. [One-year results on the safety and efficacy of the InnFocus MicroShunt depending on placement and concentration of mitomycin C]. J Fr Ophtalmol 2015; 38(9):855-860. https://doi.org/10.1016/j.jfo.2015.05.005.

18. Pinchuk L., Riss I., Batlle J.F., Kato Y.P., et al. The use of poly(styreneblock-isobutylene-block-styrene) as a microshunt to treat glaucoma. Regen Biomater 2016; 3(2):137-142. https://doi.org/10.1093/rb/rbw005.

19. Batlle J.F., Fantes F., Riss I., Pinchuk L., et al. Three-Year Follow-up of a Novel Aqueous Humor MicroShunt. J Glaucoma 2016; 25(2): e58-65. https://doi.org/10.1097/IJG.0000000000000368.

20. Batlle J.F., Corona A., Albuquerque R. Long-term Results of the PRESERFLO MicroShunt in Patients With Primary Open-angle Glaucoma From a Single-center Nonrandomized Study. J Glaucoma 2021; 30(3):281-286. https://doi.org/10.1097/IJG.0000000000001734.

21. Schlenker M.B., Durr G.M., Michaelov E., Ahmed I.I.K. Intermediate Outcomes of a Novel Standalone Ab Externo SIBS Microshunt With Mitomycin C. Am J Ophthalmol 2020; 215:141-153. https://doi.org/10.1016/j.ajo.2020.02.020.

22. Beckers H.J.M., Aptel F., Webers C.A.B., Bluwol E., et al. Safety and Effectiveness of the PRESERFLO(R) MicroShunt in Primary OpenAngle Glaucoma: Results from a 2-Year Multicenter Study. Ophthalmol Glaucoma 2022; 5(2):195-209. https://doi.org/10.1016/j.ogla.2021.07.008.

23. Pietris J., Casson R. One-Year Outcomes of Preserflo Microshunt for Primary Open Angle Glaucoma: A Systematic Review and MetaAnalysis. J Glaucoma 2024; 33(7):e27-e34. https://doi.org/10.1097/IJG.0000000000002419.

24. Першин К.Б., Пашинова Н.Ф., Цыганков А.Ю., Корнеева Е.А., Соловьева Г.М. Предварительные результаты имплантации микрошунта PreserFlo® у пациентов с первичной открытоугольной глаукомой. Национальный журнал глаукома 2025; 24(1):24-31. https://doi.org/10.53432/2078-4104-2025-24-1-24-31.

25. Martínez-de-la-Casa J.M., Saenz-Francés F., Morales-Fernandez L., Perucho L., et al. Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients. Sci Rep 2021; 11(1):15600. https://doi.org/10.1038/s41598-021-95217-x.

26. Fili S., Kontopoulou K., Vastardis I., Perdikakis G., Bechrakis N., Kohlhaas M. PreserFlo MicroShunt Combined with Phacoemulsification versus PreserFlo MicroShunt as a Standalone Procedure in Patients with Medically Resistant Open-Angle Glaucoma. J Curr Ophthalmol 2022; 34(2):180-186. https://doi.org/10.4103/joco.joco_298_21.

27. Fea A.M., Laffi G.L., Martini E., Economou M.A., et al. Effectiveness of MicroShunt in Patients with Primary Open-Angle and Pseudoexfoliative Glaucoma: A Retrospective European Multicenter Study. Ophthalmol Glaucoma 2022; 5(2):210-218. https://doi.org/10.1016/j.ogla.2021.08.005.

28. Grobshäuser E., Cunha Vaz Martinho A., Gatzioufas Z., Hasler P., Maloca P., Gugleta K. Investigation of Endothelial Cell Density after PreserFlo Implantation Compared to Contralateral Eyes without PreserFlo Implantation — A Retrospective Analysis. Klin Monbl Augenheilkd 2025. https://doi.org/10.1055/a-2495-8580.

29. Gassel C.J., Wenzel D.A., Nasyrov E., Strasser T., Voykov B. Intermediate-term impact on corneal endothelial cells and efficacy of Preserflo MicroShunt implantation in patients with open-angle glaucoma — a prospective study over two years. Graefes Arch Clin Exp Ophthalmol 2024; 262(11):3661-3670. https://doi.org/10.1007/s00417-024-06508-8.

30. Anton Steindor F., Trigaux C., Holtmann C., Spaniol K., Geerling G., Borrelli M. Preserflo MicroShunt: Efficacy and Endothelial Cell Density. J Glaucoma 2023; 32(12):1018-1021. https://doi.org/10.1097/IJG.0000000000002325.

31. Bourauel L., Petrak M., Holz F.G., Mercieca K., Weber C. Short-Term Safety and Efficacy of PreserFlo Microshunt in Patients with Refractory Intraocular Pressure Elevation After Dexamethasone Implant Intravitreal Injection. J Clin Med 2025; 14(2). https://doi.org/10.3390/jcm14020507.

32. Rezkallah A., Loria O., Mathis T., Chacun S., Denis P., Kodjikian L. Preserflo Microshunt Surgery for Ocular Hypertension following Intravitreal Fluocinolone Acetonide Implant Removal: A Case Report. Case Rep Ophthalmol 2022; 13(3):1024-1029. https://doi.org/10.1159/000527672.

33. Nasyrov E., Seppelfricke C., Doycheva D., Gassel C.J., Merle D.A., Voykov B. Preserflo MicroShunt Implantation for Glaucoma Secondary to Viral and Juvenile Idiopathic Arthritis-Related Anterior Uveitis. Ocul Immunol Inflamm 2024:1-8. https://doi.org/10.1080/09273948.2024.2436101.

34. Triolo G., Wang J., Aguilar-Munoa S., Jayaram H., Barton K. Preserflo microshunt implant for the treatment of refractory uveitic glaucoma: 36-month outcomes. Eye (Lond) 2023; 37(12):2535-2541. https://doi.org/10.1038/s41433-022-02368-w.

35. Ruparelia S., Darwich R., Eadie B.D. PreserFlo Microshunt for the management of intraocular pressure elevation in iridocorneal endothelial syndrome. Am J Ophthalmol Case Rep 2023; 32:101932. https://doi.org/10.1016/j.ajoc.2023.101932.

36. Martinez-de-la-Casa J.M., Saenz-Frances F., Morales Fernandez L., Garcia-Feijoo J. Posterior chamber implantation of a Preserflo Microshunt in a patient with a compromised endothelium. Arch Soc Esp Oftalmol (Engl Ed) 2022; 97(3):161-164. https://doi.org/10.1016/j.oftale.2022.02.002.

37. Dervos T., Gugleta K., Scholl H.P.N., Gatzioufas Z., Enz T.J. Single versus Double PreserFlo MicroShunt Implantation in Glaucoma Patients: A Retrospective Cohort Study. Ophthalmic Res 2023; 66(1):1362- 1375. https://doi.org/10.1159/000535276.

38. Majtanova N., Takacova A., Kurilova V., Hejsek L., Majtan J., Kolar P. One-Year Comparison of Efficacy and Safety of PreserFlo MicroShunt with Mitomycin C Applied by Sub-Tenon Injection Versus Sponge. Ophthalmol Ther 2025; 14(1):153-167. https://doi.org/10.1007/s40123-024-01074-y.

39. Strzalkowska A., Strzalkowski P., Hoffmann E.M., Pfeiffer N., Schuster A.K. Outcomes of Open Bleb Revision After PreserFlo MicroShunt Failure in Patients With Glaucoma. J Glaucoma 2023; 32(8):681-685. https://doi.org/10.1097/IJG.0000000000002246.

40. Governatori L., Oliverio L., Mermoud A., Scampoli A., et al. PreserFlo MicroShunt versus trabeculectomy: an updated meta-analysis and systematic review. Graefes Arch Clin Exp Ophthalmol 2024. https://doi.org/10.1007/s00417-024-06649-w.

41. Khan A., Khan A.U. Comparing the safety and efficacy of Preserflo Microshunt implantation and trabeculectomy for glaucoma: A systematic review and meta-analysis. Acta Ophthalmol 2024; 102(4): e443-e451. https://doi.org/10.1111/aos.16658.

42. Nakakura S., Oogi S., Terao E., Nagata Y., et al. Changes in Ocular Biometry Following PreserFlo MicroShunt Implantation and Trabeculectomy: A Prospective Observational Study. Cureus 2024; 16(3): e56188. https://doi.org/10.7759/cureus.56188.

43. Qidwai U., Jones L., Ratnarajan G. A comparison of iStent combined with phacoemulsification and endocyclophotocoagulation (ICE2) with the PreserFlo MicroShunt and XEN-45 implants. Ther Adv Ophthalmol 2022; 14:25158414221125697. https://doi.org/10.1177/25158414221125697.

44. Marolo P., Reibaldi M., Fallico M., Maugeri A., et al. Reintervention rate in glaucoma filtering surgery: A systematic review and meta-analysis. Eur J Ophthalmol 2022; 32(5):2515-2531. https://doi.org/10.1177/11206721221093828.

45. Scheres L.M.J., Kujovic-Aleksov S., Ramdas W.D., de Crom R., et al. XEN((R)) Gel Stent compared to PRESERFLO MicroShunt implantation for primary open-angle glaucoma: two-year results. Acta Ophthalmol 2021; 99(3):e433-e440. https://doi.org/10.1111/aos.14602.

46. Wagner F.M., Schuster A.K., Munder A., Muehl M., et al. Comparison of subconjunctival microinvasive glaucoma surgery and trabeculectomy. Acta Ophthalmol 2022; 100(5):e1120-e1126. https://doi.org/10.1111/aos.15042.

47. Nobl M., Freissinger S., Rudolph K., Vounotrypidis E., et al. Long-term Outcomes of PreserFlo MicroShunt versus XEN45 Gel Stent in OpenAngle Glaucoma. Klin Monbl Augenheilkd 2024; 241(7):805-812. https://doi.org/10.1055/a-2152-8455.

48. Lüke J.N., Dietlein T.S., Widder R.A., Roessler G.F., et al. Matched case-control comparison of surgical success after XEN45 Gel Stent and PRESERFLO MicroShunt implantation in a Caucasian population. Clin Exp Ophthalmol 2024; 52(7):732-739. https://doi.org/10.1111/ceo.14407.

49. María Martínez-de-la-Casa J.M., Pascual-Santiago A., Morales-Fernandez L., Saez-Frances F., et al. Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma. Sci Rep 2025; 15(1):1634. https://doi.org/10.1038/s41598-024-81616-3.

50. Gambini G., Carla M.M., Giannuzzi F., Boselli F., et al. Anterior Segment-Optical Coherence Tomography Bleb Morphology Comparison in Minimally Invasive Glaucoma Surgery: XEN Gel Stent vs. PreserFlo MicroShunt. Diagnostics (Basel) 2022; 12(5). https://doi.org/10.3390/diagnostics12051250.

51. Hasan S.M., Theilig T., Papadimitriou M., Meller D. A Comparative Analysis of Morphology and Dimensions of Functional Blebs following PRESERFLO-Microshunt and XEN-Gel-Stent, a Study Using Anterior Segment OCT. Diagnostics (Basel) 2023; 13(14). https://doi.org/10.3390/diagnostics13142318.

52. Neubauer J., Suesskind D., Gassel C.J., Nasyrov E., Voykov B. Histopathological findings of failed blebs after microinvasive bleb surgery with the XEN Gel Stent and Preserflo MicroShunt. Graefes Arch Clin Exp Ophthalmol 2024; 262(9):2977-2984. https://doi.org/10.1007/s00417-024-06479-w.

53. Theilig T., Papadimitriou M., Albaba G., Meller D., Hasan S.M. Results of open bleb revision as management of primary bleb failure following XEN 45 gel stent and Preserflo Microshunt. Graefes Arch Clin Exp Ophthalmol 2023; 261(11):3249-3255. https://doi.org/10.1007/s00417-023-06152-8.

54. Steiner S., Resch H., Kiss B., Vass C. PRESERFLO Microshunt: 1-Year Results of a 25-Gauge vs. 27-Gauge Needle Tract. J Clin Med 2024; 13(7). https://doi.org/10.3390/jcm13071979.

55. Fea A.M., Ghilardi A., Bovone D., Reibaldi M., Rossi A., Craven E.R. A New and Easier Approach to Preserflo MicroShunt Implantation. Clin Ophthalmol 2022; 16:1281-1288. https://doi.org/10.2147/OPTH.S307835.

56. Miura Y., Fukuda K., Yamashiro K. Comparison of outcomes with and without intrastent placement during PMS surgery. Sci Rep 2025; 15(1):2981. https://doi.org/10.1038/s41598-025-87259-2.

57. Verma-Fuehring R., Dakroub M., Bamousa A., Kann G., Hillenkamp J., Kampik D. The use of intraluminal PRESERFLO stenting in avoiding early postoperative hypotony. Graefes Arch Clin Exp Ophthalmol 2024; 262(12):3925-3932. https://doi.org/10.1007/s00417-024-06567-x.

58. Miura Y., Fukuda K., Yamashiro K. Ab Interno Intraluminal Stent Insertion for Prolonged Hypotony After PreserFlo MicroShunt Implantation. Cureus 2024; 16(5):e60221. https://doi.org/10.7759/cureus.60221.

59. Lupardi E., Laffi G.L., Moramarco A., Barboni P., Fontana L. Systematic Preserflo MicroShunt Intraluminal Stenting for Hypotony Prevention in Highly Myopic Patients: A Comparative Study. J Clin Med 2023; 12(4):1677. https://doi.org/10.3390/jcm12041677.

60. Schneider S., Kallab M., Murauer O., Reisinger A.S., et al. Bleb vessel density as a predictive factor for surgical revisions after Preserflo Microshunt implantation. Acta Ophthalmol 2024; 102(5):e797-e804. https://doi.org/10.1111/aos.16642.

61. Cagini C., Boni N., Bonifazi T., Fruttini D., Della Lena F. Efficacy and Safety of PreserFlo MicroShunt Implantation and Its Effects on Intraocular Inflammation through Laser Flare Photometry. J Ophthalmol 2024; 2024:2447721. https://doi.org/10.1155/2024/2447721.

62. Rojo-Arnao M., Martinez-de-la-Casa J.M., Albis-Donado O., YanezCastro G., et al. Preserflo TM MicroShunt implantation combined with Ologen TM in primary and secondary glaucoma patients in a clinical setting. Indian J Ophthalmol 2024; 72(3):417-426. https://doi.org/10.4103/IJO.IJO_1502_23.

63. Nakakura S., Nagata Y., Fujisawa Y., Kiuchi Y. Scleral bridging technique for preventing PreserFlo microshunt exposure: A case report. Medicine (Baltimore) 2024; 103(27):e38847. https://doi.org/10.1097/MD.0000000000038847.

64. Morales-Fernández L., Pérez-García P., Martínez-de-la-Casa J.M., Sáenz-Francés F., et al. Intraoperative OCT to check the correct postimplant position of Preserflo(TM). Eur J Ophthalmol 2024: 11206721241272169. https://doi.org/10.1177/11206721241272169.